Print
Email
Print Edition Stories
Life sciences-focused Third Rock Ventures LLC has added Daniel S. Lynch, former CEO of ImClone Systems Inc., as entrepreneur-in-residence at the venture capital firm.
Lynch most recently has been serving as executive chairman of both Avila Therapeutics Inc. and Stromedix Inc. At ImClone, where he also held the CFO post in addition to the CEO role, he led the FDA approval of cancer treatment Erbitux and negotiated partnership with Bristol-Myers Squibb. Prior to ImClone, he held financial positions at Bristol-Myers Squibb. He now is a board member of bluebird bio, a portfolio company of Third Rock Ventures.
Lynch earned an MBA from the University of Virginia and a bachelor’s degree from Wesleyan University.
Third Rock Ventures has offices in both Boston and San Francisco. Its portfolio companies include Ablexis, Afferent Pharmaceuticals, Agios Pharmaceuticals, Alnara Pharmaceuticals (acquired by Eli Lilly & Co. in 2010), bluebird bio, Blueprint Medicines, Constellation Pharmaceuticals, CytomX Therapeutics, DC Devices, Edimer Pharmaceuticals, Eleven Biotherapeutics, Foundation Medicine, Kala Pharmaceuticals, Nine Point Medical, PanOptica Pharmaceuticals, Rhythm Pharmaceuticals, Seventh Sense Biosystems, Taris Biomedical and Zafgen.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
